DE69618587D1 - Chinazoline und pharmazeutische zusammensetzungen - Google Patents
Chinazoline und pharmazeutische zusammensetzungenInfo
- Publication number
- DE69618587D1 DE69618587D1 DE69618587T DE69618587T DE69618587D1 DE 69618587 D1 DE69618587 D1 DE 69618587D1 DE 69618587 T DE69618587 T DE 69618587T DE 69618587 T DE69618587 T DE 69618587T DE 69618587 D1 DE69618587 D1 DE 69618587D1
- Authority
- DE
- Germany
- Prior art keywords
- chinazoline
- pharmaceutical compositions
- pharmaceutical
- compositions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/74—Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US48058995A | 1995-06-07 | 1995-06-07 | |
PCT/US1996/008877 WO1996040648A1 (en) | 1995-06-07 | 1996-06-04 | Quinazolines and pharmaceutical compositions |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69618587D1 true DE69618587D1 (de) | 2002-02-21 |
DE69618587T2 DE69618587T2 (de) | 2002-08-29 |
Family
ID=23908543
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69618587T Expired - Fee Related DE69618587T2 (de) | 1995-06-07 | 1996-06-04 | Chinazoline und pharmazeutische zusammensetzungen |
Country Status (7)
Country | Link |
---|---|
US (1) | US6103728A (de) |
EP (1) | EP0832073B1 (de) |
JP (1) | JPH11507052A (de) |
AU (1) | AU5984296A (de) |
CA (1) | CA2222545A1 (de) |
DE (1) | DE69618587T2 (de) |
WO (1) | WO1996040648A1 (de) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6645969B1 (en) | 1991-05-10 | 2003-11-11 | Aventis Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase |
TW321649B (de) * | 1994-11-12 | 1997-12-01 | Zeneca Ltd | |
GB9424233D0 (en) * | 1994-11-30 | 1995-01-18 | Zeneca Ltd | Quinazoline derivatives |
JPH11507329A (ja) * | 1995-04-27 | 1999-06-29 | ゼネカ リミテッド | キナゾリン誘導体 |
GB9508565D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
GB9508538D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
GB9508535D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivative |
GB9508537D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
GB9624482D0 (en) * | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
AU719434B2 (en) | 1996-02-13 | 2000-05-11 | Astrazeneca Ab | Quinazoline derivatives as VEGF inhibitors |
GB9603097D0 (en) * | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline compounds |
GB9603095D0 (en) * | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
CA2244897C (en) | 1996-03-05 | 2006-04-11 | Zeneca Limited | 4-anilinoquinazoline derivatives |
BR9708640B1 (pt) | 1996-04-12 | 2013-06-11 | inibidores irreversÍveis de tirosina-cinases e composiÇço farmacÊutica compreendendo os mesmo. | |
GB9607729D0 (en) * | 1996-04-13 | 1996-06-19 | Zeneca Ltd | Quinazoline derivatives |
GB9707800D0 (en) | 1996-05-06 | 1997-06-04 | Zeneca Ltd | Chemical compounds |
GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
CN1252054C (zh) | 1996-09-25 | 2006-04-19 | 曾尼卡有限公司 | 抑制生长因子的作用的喹啉衍生物 |
WO1998038984A2 (en) | 1997-03-05 | 1998-09-11 | Sugen, Inc. | Formulations for hydrophobic pharmaceutical agents |
US6294532B1 (en) | 1997-08-22 | 2001-09-25 | Zeneca Limited | Oxindolylquinazoline derivatives as angiogenesis inhibitors |
EP1082311A1 (de) | 1998-05-28 | 2001-03-14 | Parker Hughes Institute | Chinazolinen fur die behandlung von gehirnstumor |
US6800649B1 (en) | 1998-06-30 | 2004-10-05 | Parker Hughes Institute | Method for inhibiting c-jun expression using JAK-3 inhibitors |
EP1510212A1 (de) * | 1998-08-21 | 2005-03-02 | Parker Hughes Institute | Verwendung von 4-substituerte Chinazolin-Derivaten zur Herstellung von therapeutischen Mitteln |
HUP0103386A3 (en) | 1998-08-21 | 2002-07-29 | Parker Hughes Inst St Paul | Use of quinazoline derivatives for producing pharmaceutical compositions having jak 3-inhibitor effect |
US6258820B1 (en) | 1999-03-19 | 2001-07-10 | Parker Hughes Institute | Synthesis and anti-tumor activity of 6,7-dialkoxy-4-phenylamino-quinazolines |
US7064114B2 (en) | 1999-03-19 | 2006-06-20 | Parker Hughes Institute | Gel-microemulsion formulations |
GB9918057D0 (en) * | 1999-07-30 | 1999-10-06 | Univ Bristol | Therapeutic agents |
SI1676845T1 (sl) | 1999-11-05 | 2008-10-31 | Astrazeneca Ab | Novi kinazolinski derivati |
US20090197852A9 (en) * | 2001-08-06 | 2009-08-06 | Johnson Robert G Jr | Method of treating breast cancer using 17-AAG or 17-AG or a prodrug of either in combination with a HER2 inhibitor |
CA2491191C (en) | 2002-07-15 | 2014-02-04 | Exelixis, Inc. | Receptor-type kinase modulators and methods of use |
CA2494061C (en) * | 2002-07-31 | 2011-06-14 | Wayne R. Danter | Protein tyrosine kinase inhibitors |
ATE380810T1 (de) * | 2002-10-09 | 2007-12-15 | Critical Outcome Technologies | Protein-tyrosine-kinase-inhibitoren |
ATE517091T1 (de) | 2003-09-26 | 2011-08-15 | Exelixis Inc | C-met-modulatoren und verwendungsverfahren |
US20070093515A1 (en) * | 2005-08-16 | 2007-04-26 | Arrington Mark P | Phosphodiesterase 10 inhibitors |
US20070265256A1 (en) * | 2006-02-21 | 2007-11-15 | Arrington Mark P | Phosphodiesterase 10 inhibitors |
CA2643044A1 (en) * | 2006-02-28 | 2007-09-07 | Amgen Inc. | Cinnoline and quinazoline derivates as phosphodiesterase 10 inhibitors |
CA2660836A1 (en) | 2006-08-07 | 2008-02-21 | Incyte Corporation | Triazolotriazines as kinase inhibitors |
US8034815B2 (en) | 2007-01-11 | 2011-10-11 | Critical Outcome Technologies, Inc. | Compounds and method for treatment of cancer |
WO2009079797A1 (en) * | 2007-12-26 | 2009-07-02 | Critical Outcome Technologies, Inc. | Compounds and method for treatment of cancer |
EP3023426A1 (de) | 2008-07-17 | 2016-05-25 | Critical Outcome Technologies, Inc. | Thiosemicarbazonhemmerverbindungen und krebsbehandlungsverfahren |
TW202241853A (zh) | 2009-01-16 | 2022-11-01 | 美商艾克塞里克斯公司 | 包含n-(4-{[6,7-雙(甲氧基)喹啉-4-基]氧基}苯基)-n'-(4-氟苯基)環丙烷-1,1-二甲醯胺之蘋果酸鹽之醫藥組合物及其用途 |
UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
CA2794952C (en) | 2010-04-01 | 2018-05-15 | Critical Outcome Technologies Inc. | Compounds and method for treatment of hiv |
CA2828713C (en) | 2011-03-04 | 2022-08-16 | Newgen Therapeutics, Inc. | Alkyne substituted quinazoline compounds and methods of use |
FR3019819B1 (fr) | 2014-04-09 | 2018-03-23 | Centre National De La Recherche Scientifique (Cnrs) | Composes cytotoxiques inhibiteurs de la polymerisation de la tubuline |
US20190112317A1 (en) | 2015-10-05 | 2019-04-18 | The Trustees Of Columbia University In The City Of New York | Activators of autophagic flux and phospholipase d and clearance of protein aggregates including tau and treatment of proteinopathies |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US36256A (en) * | 1862-08-19 | Improvement in sewing-m ach ines | ||
US3266990A (en) * | 1963-09-24 | 1966-08-16 | Warner Lambert Pharmaceutical | Derivatives of quinazoline |
US3800039A (en) * | 1970-10-21 | 1974-03-26 | Mead Johnson & Co | Antithrombogenic process employing substituted 6,7-dialkoxyquinazolines |
US4343940A (en) * | 1979-02-13 | 1982-08-10 | Mead Johnson & Company | Anti-tumor quinazoline compounds |
GB2065653B (en) * | 1979-12-19 | 1983-03-09 | Nat Res Dev | Anti-cancer quinazoline derivatives |
US4966849A (en) * | 1985-09-20 | 1990-10-30 | President And Fellows Of Harvard College | CDNA and genes for human angiogenin (angiogenesis factor) and methods of expression |
DE3611194A1 (de) * | 1986-04-04 | 1987-10-08 | Bayer Ag | Cancerostatisches mittel |
US5217999A (en) * | 1987-12-24 | 1993-06-08 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Styryl compounds which inhibit EGF receptor protein tyrosine kinase |
IL89027A (en) * | 1988-01-29 | 1993-01-31 | Lilly Co Eli | Quinazoline derivatives, process for their preparation and fungicidal, insecticidal and miticidal compositions containing them |
DE3920029C2 (de) * | 1988-06-30 | 1999-05-20 | Clariant Finance Bvi Ltd | Farbstoffe zum Färben von Kunststoffen |
DE69105495T2 (de) * | 1990-04-02 | 1995-04-06 | Pfizer | Benzylphosphonsäure-tyrosinkinaseinhibitoren. |
US5302606A (en) * | 1990-04-16 | 1994-04-12 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase |
ES2108120T3 (es) * | 1991-05-10 | 1997-12-16 | Rhone Poulenc Rorer Int | Compuestos bis arilicos y heteroarilicos mono- y biciclicos que inhiben tirosina quinasa receptora de egf y/o pdgf. |
US5721237A (en) * | 1991-05-10 | 1998-02-24 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties |
US5480883A (en) | 1991-05-10 | 1996-01-02 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
US5710158A (en) * | 1991-05-10 | 1998-01-20 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
JPH06503095A (ja) * | 1991-05-29 | 1994-04-07 | ファイザー・インコーポレーテッド | 三環式ポリヒドロキシ系のチロシンキナーゼ阻害薬 |
NZ243082A (en) * | 1991-06-28 | 1995-02-24 | Ici Plc | 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof |
AU661533B2 (en) * | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
GB9205320D0 (en) * | 1992-03-11 | 1992-04-22 | Ici Plc | Anti-tumour compounds |
JPH08503450A (ja) * | 1992-08-06 | 1996-04-16 | ワーナー−ランバート・コンパニー | 蛋白チロシンキナーゼを阻害し、かつ抗腫瘍特性を有する2−チオインドール(セレノインドール)および関連ジスルフィド(セレニド) |
US5330992A (en) * | 1992-10-23 | 1994-07-19 | Sterling Winthrop Inc. | 1-cyclopropyl-4-pyridyl-quinolinones |
BR9207175A (pt) * | 1992-10-28 | 1995-12-12 | Genentech Inc | Composição contendo antagonista de fator de crescimento de célula endotelial vascular sequência aminoácida de anticorpo monoclonal polipeptídeo e método de tratamento de tumor em mamífero |
GB9226855D0 (en) * | 1992-12-23 | 1993-02-17 | Erba Carlo Spa | Vinylene-azaindole derivatives and process for their preparation |
GB9716557D0 (en) * | 1997-08-06 | 1997-10-08 | Glaxo Group Ltd | Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity |
-
1996
- 1996-06-04 JP JP9501345A patent/JPH11507052A/ja not_active Withdrawn
- 1996-06-04 DE DE69618587T patent/DE69618587T2/de not_active Expired - Fee Related
- 1996-06-04 EP EP96917174A patent/EP0832073B1/de not_active Expired - Lifetime
- 1996-06-04 AU AU59842/96A patent/AU5984296A/en not_active Abandoned
- 1996-06-04 WO PCT/US1996/008877 patent/WO1996040648A1/en active IP Right Grant
- 1996-06-04 CA CA002222545A patent/CA2222545A1/en not_active Abandoned
-
1997
- 1997-02-28 US US08/807,339 patent/US6103728A/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
WO1996040648A1 (en) | 1996-12-19 |
EP0832073A1 (de) | 1998-04-01 |
JPH11507052A (ja) | 1999-06-22 |
AU5984296A (en) | 1996-12-30 |
DE69618587T2 (de) | 2002-08-29 |
US6103728A (en) | 2000-08-15 |
EP0832073B1 (de) | 2002-01-16 |
CA2222545A1 (en) | 1996-12-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69618587T2 (de) | Chinazoline und pharmazeutische zusammensetzungen | |
DE69525148T2 (de) | Pharmazeutische formulierung | |
NO20021172D0 (no) | Farmasöytisk sammensetning | |
BR9607317A (pt) | Peptídios e composição farmacêutica | |
BR9607318A (pt) | Peptidos e composição farmacêutica | |
BR9611367A (pt) | Formulação farmacêutic liofilizada estável | |
BR9610153A (pt) | Formulações farmacêuticas | |
BR9611626A (pt) | Formulações farmacéuticas | |
BR9607851B1 (pt) | combinaÇço e formulaÇço farmacÊutica. | |
NO981008D0 (no) | Farmasöytisk formulering | |
BR9602915A (pt) | Medicamentos uso e formulação farmacêutica | |
DE69524592D1 (de) | 2-Acylaminopropanolverbindung und ihre pharmazeutische Zusammensetzung | |
BR9509688A (pt) | Composto e composição farmacêutica | |
DE69614407T2 (de) | Pharmazeutische zusammensetzungen | |
LV11727A (lv) | Farmaceitiska kompozicija | |
ATE295150T1 (de) | Pharmazeutische zusammensetzungen | |
ATE228839T1 (de) | Tizoxanide und nitazoxanide enthaltende pharmazeutische zusammensetzungen | |
FI973280A0 (fi) | Farmaseuttinen koostumus | |
FI973230A (fi) | Uusi farmaseuttinen formulaatio | |
BR9606066A (pt) | Composto e formulação farmacêutica | |
DE69509621T2 (de) | Diarylheptanoidderivat und diese enthaltende pharmazeutische Zusammensetzung | |
BR9605777A (pt) | Composição farmacêutica | |
BR9505130A (pt) | Composto e composiçao farmacêutica | |
BR9605220A (pt) | Gonadotropinas e composiçao farmacêutica | |
NO964309D0 (no) | Farmasöytisk sammensetning |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8339 | Ceased/non-payment of the annual fee |